Market Cap 3.52B
Revenue (ttm) 0.00
Net Income (ttm) -118.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.18
Volume 386,700
Avg Vol 529,606
Day's Range N/A - N/A
Shares Out 64.01M
Stochastic %K 71%
Beta 1.27
Analysts Strong Sell
Price Target $77.00

Company Profile

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Phone: 41 415108022
Address:
Dorfstrasse 29, Zug, Switzerland
S_Franconi
S_Franconi Jul. 23 at 2:48 PM
0 · Reply
Irish_lass
Irish_lass Jul. 23 at 2:37 PM
$MLTX Yes indeed!
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
CarbonSpirit
CarbonSpirit Jul. 18 at 3:23 PM
$MLTX and of course its options expiry day today, so it could be a very lively sell off heavy for all heavily shorted stocks today.
0 · Reply
CarbonSpirit
CarbonSpirit Jul. 18 at 3:21 PM
$MLTX a near to medium term of data catalyst heavy opportunity, if they show differentiation versus UCB Bimzelx , then it’s a major value catalyst and will instigate M&A outreach
1 · Reply
S_Franconi
S_Franconi Jul. 18 at 2:03 PM
0 · Reply
ZR92x
ZR92x Jul. 17 at 8:40 PM
$MLTX me the last few days watching this stock. uhh what?
0 · Reply
Irish_lass
Irish_lass Jul. 17 at 3:21 PM
0 · Reply
MaverikIT
MaverikIT Jul. 17 at 2:04 PM
$MRUS +3.67 - nice affter P2 data $ONC $KRYS $MLTX
0 · Reply
Doozio
Doozio Jul. 17 at 2:50 AM
$MLTX 🐒🍌🧠⏰♾️
0 · Reply
Latest News on MLTX
MoonLake Immunotherapeutics: A Buy At Dips

Apr 8, 2025, 3:31 AM EDT - 3 months ago

MoonLake Immunotherapeutics: A Buy At Dips


MoonLake Immunotherapeutics Is Now Thoroughly De-Risked

Sep 27, 2023, 8:00 PM EDT - 1 year ago

MoonLake Immunotherapeutics Is Now Thoroughly De-Risked


Strong Mid-Cap Insider Buys: Q2 2023

Jul 24, 2023, 2:45 PM EDT - 2 years ago

Strong Mid-Cap Insider Buys: Q2 2023

ABCB ADC CLF CNX DISH EWBC GME


Exclusive: MoonLake Immunotherapeutics explores sale-sources

Jul 14, 2023, 3:38 PM EDT - 2 years ago

Exclusive: MoonLake Immunotherapeutics explores sale-sources


MoonLake: Further Gains Possible With End Of 2023 Data Releases

Jun 27, 2023, 5:50 PM EDT - 2 years ago

MoonLake: Further Gains Possible With End Of 2023 Data Releases


Why MoonLake Immunotherapeutics Shares Are Surging Higher Today

May 31, 2022, 9:24 AM EDT - 3 years ago

Why MoonLake Immunotherapeutics Shares Are Surging Higher Today


S_Franconi
S_Franconi Jul. 23 at 2:48 PM
0 · Reply
Irish_lass
Irish_lass Jul. 23 at 2:37 PM
$MLTX Yes indeed!
0 · Reply
Quantumup
Quantumup Jul. 21 at 1:15 PM
Stifel reiterated $ORKA Buy-$47 after $ORKA's disclosure of the IND clearance for ORKA-001 and then catching up w/ mgmt.. $ABBV $PTGX $JNJ #EADV25 UCBJY $MLTX Stifel said in its note: "We caught up with management who noted that the IND clearance was based on interim Ph1 data (safety/tolerability) and Ph2a sites are open and actively enrolling -- Ph1 results to be presented at #EADV in September. Recall, ORKA-001 is a next-gen IL-23p19 which is designed to explore greater exposure and improved dosing vs. mega-blockbuster Skyrizi based on exploratory IST results in Psoriasis demonstrating superior efficacy/potential for remission in patients dosed with 4x the normal psoriasis dose (LINK). Meanwhile, $ORKA is on track to release Ph1 data for ORKA-002 (next-gen IL-17A/F mAb) by YE25 following a continued strong launch for Bimzelx and upcoming Ph3 data for $MLTX's sonelokimab -- there is currently limited investor focus on $ORKA as a player in the IL-17A/F space."
0 · Reply
CarbonSpirit
CarbonSpirit Jul. 18 at 3:23 PM
$MLTX and of course its options expiry day today, so it could be a very lively sell off heavy for all heavily shorted stocks today.
0 · Reply
CarbonSpirit
CarbonSpirit Jul. 18 at 3:21 PM
$MLTX a near to medium term of data catalyst heavy opportunity, if they show differentiation versus UCB Bimzelx , then it’s a major value catalyst and will instigate M&A outreach
1 · Reply
S_Franconi
S_Franconi Jul. 18 at 2:03 PM
0 · Reply
ZR92x
ZR92x Jul. 17 at 8:40 PM
$MLTX me the last few days watching this stock. uhh what?
0 · Reply
Irish_lass
Irish_lass Jul. 17 at 3:21 PM
0 · Reply
MaverikIT
MaverikIT Jul. 17 at 2:04 PM
$MRUS +3.67 - nice affter P2 data $ONC $KRYS $MLTX
0 · Reply
Doozio
Doozio Jul. 17 at 2:50 AM
$MLTX 🐒🍌🧠⏰♾️
0 · Reply
Irish_lass
Irish_lass Jul. 16 at 8:30 PM
0 · Reply
bhavn008
bhavn008 Jul. 11 at 3:45 PM
$MLTX Bought MoonLake Therapeutics stock The company will unveil week-16 topline data from its twin Phase 3 VELA trials in hidradenitis suppurativa likely in September. VELA is the first Phase 3 HS program to use the tougher HiSCR75 endpoint, mirroring the Phase 2 MIRA design with sonelokimab 120 mg vs placebo. Phase 2 MIRA already delivered a 29-point HiSCR75 delta (43 % vs 15 % placebo) at 12 weeks, de-risking the ≥20-point goal investors are watching. Efficacy is much higher than currently approved drugs like Adalimumab, secukinumab. Reproducing that gap would position sonelokimab as a potential best-in-class IL-17A/F therapy for HS patients. HS is expected to reach $1.8 billion/year market by 2031. I am optimistic on successful readout for the catalyst. Cash reserves of $480M are adequate for at least next 12 months. Phase 3 for sonelokimab in psoriatic arthritis in H1 2026 is another significant near-term catalyst. Long MLTX. Not an investment advice.
1 · Reply
ZR92x
ZR92x Jul. 9 at 11:10 AM
$MLTX Merck just bought Verona Pharma for $10 billion today. peak sales of VRNA expected around $3 billion. MoonLake expected sales around $4.5 billion. this means Moonlake should be valued above $10 billion by Merck also…
1 · Reply
ZR92x
ZR92x Jul. 8 at 8:44 PM
$MLTX i think the CEO is going to sell to Merck eventually but not until after more value creation. $3 billion offer from Merck was a too low-ball of an offer. This company has Ph3 HS, Ph3 HS (teenagers), Ph2 PPP, Ph2 axSpA, Ph3 PsA results... all in the next 6-9 months. that is a lot of value creation opportunities in a very short timeframe upcoming. i expect best in class results from all of them. HS data is crazy good. Phase 2 - 43.3% HiSCR75 at 12 weeks and a whopping 60% HiSCR75 at 24 weeks!! They could be at 50%+ HiSCR75 for Phase 3 in 16 weeks duration... that would be twice as much for HiSCR75 as Consentyx in the same time period. that is really really really good. 30% had HiSCR100 in 24 weeks. That is complete clearance in 1/3rd of patients!!! Interim PPP Phase 2 data looks extremely good also.
0 · Reply
Doozio
Doozio Jul. 4 at 5:13 PM
Out of 🐑⏰♾️ MAMA said da cup n handle BROS where going biotech $MLTX by da summer lake during 🐒🍌🧠⏰♾️
1 · Reply
bigkahunatrader
bigkahunatrader Jul. 2 at 6:14 AM
$MLTX Moonlake Imunotherapeutics, Inc. TM-5 Cycle Trade...Stock Rating 83 https://youtu.be/miGmVtMT7RY
0 · Reply
penelope6
penelope6 Jun. 24 at 12:27 PM
$MLTX someone knocking at the door, let them in
0 · Reply
penelope6
penelope6 Jun. 18 at 4:11 PM
$MLTX up like this with light volume??? suspect.
0 · Reply
swingingtech
swingingtech Jun. 18 at 1:54 PM
$ESML $MLTX $RXST $RBBN https://wallstreetwaves.com/projected-growth-esml-could-reach-48/
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Jun. 10 at 7:31 PM
$MLTX expect $60 a share.
1 · Reply
OpenOutcrier
OpenOutcrier Jun. 9 at 11:42 AM
$MLTX (+0.0% pre) StockWatch: Report of $3B+ $MRK Merck Buyout Offer Propels MoonLake Stock Surge https://ooc.bz/l/67292
0 · Reply
BigSqueezeComing
BigSqueezeComing Jun. 9 at 1:06 AM
$MLTX bid implied a roughly 15–20% premium per share
0 · Reply